Merck initiates MOBILIZE-1 phase 3 study evaluating dengue vaccine candidate, V181

Overview

Merck, known as MSD outside of the United States and Canada, announced the initiation of the MOBILIZE-1 phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), regardless of prior dengue exposure. Recruitment for the trial has begun, and the first participants are now enrolling in Singapore.

Statement from the SVP: Merck Research Laboratories

• “Approximately half of the world’s population live in areas with a risk for dengue, making it a serious public health threat,” said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines, global clinical development, Merck Research Laboratories. 

• “The initiation of the MOBILIZE-1 study, the first phase 3 trial in our clinical development programme, marks a key milestone in our work to help address this widespread mosquito-borne disease. If successful, V181 could provide an important single-dose option for at risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe.”

Merck against dengue virus infection

Merck is committed to research and innovation that aims to help protect the millions of people at risk for dengue virus infection and is establishing a programme of clinical trials for V181, including conducting trials globally, in places where dengue is a significant health threat.

The MOBILIZE-1 trial

• MOBILIZE-1, also known as V181-005, is a phase 3, randomized, double-blind, placebo-controlled study evaluating the safety, immunogenicity and efficacy of V181, an investigational vaccine for the prevention of dengue disease. 

• The study aims to enroll approximately 12,000 healthy individuals 2 to 17 years of age who will be randomized to receive either a single dose of V181 or placebo. 

• The study is planned to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific region, including Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam. 

• The primary endpoints of the study are safety and efficacy of a single dose of V181 in preventing symptomatic virologically confirmed dengue (VCD) of any severity, due to any of the four dengue serotypes, regardless of prior dengue exposure. 

• The key secondary efficacy endpoint is evaluating a single dose of V181 in preventing symptomatic VCD of any severity due to each of the four dengue serotypes, regardless of prior dengue exposure. 

• Additional secondary endpoints include evaluating a single dose of V181 in preventing symptomatic VCD with warning signs, severe VCD and hospitalization.

About the vaccine: V181

• V181 is a live attenuated quadrivalent vaccine currently being investigated for the prevention of dengue disease caused by any of the four dengue virus types (DENV-1, DENV-2, DENV-3, and DENV-4). 

• V181 is designed to be a single-dose vaccination and is being studied in individuals to provide protection against dengue, including severe forms, whether the individuals have been previously infected with the dengue virus or had no prior infections.

 All about Dengue disease: Severity, symptoms, etc.

• Dengue disease is one of the fastest growing mosquito-borne diseases that affects not just the health but often the economic stability of communities across the globe. 

• It is a rapidly emerging cause of serious and sometimes debilitating illness in tropical and subtropical countries. 

• With approximately half of the world’s population, or four billion people, at risk for dengue disease, it represents a critical public health challenge. 

• Globally, around 105 million dengue viral infections occur annually, with approximately 50-60 million being symptomatic on average per year. 

• While the majority of infections are uncomplicated, serious illness caused by dengue can be severe and lead to death (on average, ~4-11 million cases result in hospitalizations per year and there is an average annual incidence of ~29,000 dengue-related deaths worldwide). 

• Symptoms of mild dengue fever may include a high fever, a rash and muscle and joint pain. 

• Dengue fever might evolve to severe dengue, formerly known as dengue haemorrhagic fever, which can cause severe bleeding, a sudden drop in blood pressure, and in rare cases, death.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!